NOVOCURE LTD

Novocure insider sale: a routine RSU‑driven sell‑to‑cover at $15.77 shows no major market impact; focus on pipeline milestones for long‑term value.

Novocure insider sales are routine tax‑cover moves, not a sign of trouble. Understand how the oncology tech firm’s pipeline and reimbursement strategy drive future value.